News
Published its 2025 Year in Review brochure summarizing portfolio activity and investment strategy.
Pfizer Ventures 2025 Year in Review
Added recently
6 investments· JUL 2023 – JUN 2026
Investment
Participated in Flare Therapeutics' $85M insider-led Series C, led by Third Rock Ventures and Nextech Invest.
Flare Therapeutics
JUN 30, 2026
Investment
Joined Crossbow Therapeutics' $77M Series B as a new investor, co-led by Taiho Ventures and Arkin Bio Capital.
Crossbow Therapeutics
MAR 13, 2026
Investment
Co-led Enara Bio's $32.5M Series B (with M Ventures) to advance its Dark Antigen TCR-based immunotherapy pipeline.
Enara Bio
OCT 2024
Investment
Added a $10M extension to Enlaza Therapeutics' $100M Series A, led by J.P. Morgan Private Capital's Life Sciences group.
Enlaza Therapeutics
APR 30, 2024
Investment
Led Curve Therapeutics' £40.5M Series A for its cyclic-peptide cancer drug discovery platform.
Curve Therapeutics
FEB 27, 2024
Investment
Co-led Crossbow Therapeutics' $80M Series A launch alongside MPM BioImpact.
Crossbow Therapeutics
JUL 11, 2023